Recombinant adeno-associated virus (AAV) and lentivirus (LV) are critical components of gene and cell therapies, which show incredible promise for the treatment of disease. Accordingly, the need for large-scale manufacture of safe and effective viral vectors has never been greater.
Here, we present optimization strategies for generating higher AAV and LV titers in both adherent and suspension HEK 293 cells using the TransIT-VirusGEN® Transfection Reagent. In addition, we will introduce LV and AAV enhancers that further increase functional virus titers over previously optimized conditions and expand manufacturing capabilities for gene and cell therapies.
Attendees will learn: